Skip to content

Isolated Methylmalonic Acidemia Infantile Non B12 Responsive Cn381185

Published: July 22, 2026Updated: August 20, 2026

A metabolic disorder where the body cannot break down certain amino acids. Treated with special diet and supplements.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
E88.9
ICD-11
5A00.0
Body system
metabolic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Fatigue or weight changes

(metabolic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Metabolic acidosis

(metabolic)

Failure to thrive

(metabolic)

Seizures

(metabolic)

Pancytopenia

(metabolic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Low-Protein Medical Diet

Specialized nutritional management with severe protein restriction and methionine-free, threonine-free, valine-free, isoleucine-free amino acid formulas to reduce toxic metabolite accumulation.

dietary
2

Pharmacological management with first-line agents

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
3

Metabolic Cofactor Supplementation

Administration of L-carnitine, vitamin B12, and biotin to support residual enzyme activity and improve metabolic function in affected patients.

medication

Additional treatment options

Metabolic Laboratory Monitoring

Regular blood and urine testing to monitor methylmalonic acid levels, amino acid profiles, and organ function to prevent metabolic decompensation.

monitoring

Emergency Metabolic Protocol

Structured sick-day management plan including increased calorie intake, reduced protein, and hospitalization protocols for acute illness to prevent catabolism.

lifestyle

Liver Transplantation Evaluation

Surgical assessment for liver transplantation as definitive treatment for severe, refractory cases unresponsive to dietary and medical management.

procedure

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Isolated Methylmalonic Acidemia Infantile Non B12 Responsive Cn381185?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Medication Comparisons

Compare medications used to treat Isolated Methylmalonic Acidemia Infantile Non B12 Responsive Cn381185. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy